CytomX Therapeutics, Inc.
CTMX· Nasdaq
CTMXCytomX Therapeutics, Inc.
Filed Feb 27, 2020 · 10-K · 58 days after period end · 0001564590-20-007395
| Metric | Q4 2019 | Q4 2018 | Q4 2017 | Q4 2016 |
|---|---|---|---|---|
| Revenue | $8.28M | $11.47M | $27.07M | $6.27M |
| Net Income | -$35.46M | -$32.23M | $621.00K | -$14.03M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CytomX Therapeutics, Inc. · CIK 1501989 · Engraved from SEC EDGAR
ended Dec 31, 2019 · filed Feb 27, 2020 · 58 d after period end
